Skip to main content

James Breen

ID:LEX-AR-3GAGBJ7W

/

Unclaimed

/

Organization: Goodwin Procter

FDA Schedules Public Meeting and Request for Comments on Biosimilar User Fee Act

Big Molecule Watch · September 29, 2021

Innovent Announces the Approval of a First-Line Therapy for People with Hepatocellular Carcinoma in China

Big Molecule Watch · July 9, 2021

Quebec Government Announces Shift to Biosimilar Drugs

Big Molecule Watch · May 27, 2021

Plantform and Bio-Manguinhos/Fiocrus to Partner on Pembrolizumab Biosimilar for Brazil

Big Molecule Watch · April 15, 2021

7th Circuit Evaluates the “Patent Thicket”

Big Molecule Watch · March 10, 2021